U.S. Markets close in 2 hrs 32 mins

Celgene is a big part of the biotech sector's plunge: NYSE trader

Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the biotech sector, down nearly 6% in October, focusing on the problems with Celgene, down 34% this month.